$CVS Oppenheimer is "not overly bullish" on the near-term outlook for CVS' retail/long-term care and pharmacy benefit manager businesses, which it said face company-specific pressures from contract movement. Wiederhorn also sees headwinds from industry pressures and an uncertain reimbursement environment. "Although the valuation appears attractive by historical levels, we expect these factors to dominate the story for the foreseeable future."